

Trial demonstrates acute lymphoblastic leukemia treatment advance

December 13 2022, by Diane Dragaud




Figure 2: Overall Survival



Credit: *LBA-1 Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial (2022).*

Late-breaking research reveals a major treatment advance for adults with newly diagnosed B lineage acute lymphoblastic leukemia (ALL). The randomized phase 3 study E1910 evaluated blinatumomab immunotherapy in patients with a good prognosis after an initial round of chemotherapy. After about 3.5 years of follow-up, 83% of the patients who went on to receive additional standard consolidation chemotherapy plus experimental blinatumomab were alive versus 65% of those who received chemotherapy only.

Lead researcher Mark R. Litzow, MD, presented the results of Abstract LBA-1 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition on Tuesday, December 13, 2022, at 9:00 AM Central Time. LBA-1 was the first of only six late-breaking abstracts at this meeting and was part of the official press program on Monday, December 12, at 8:30 AM CT.

"The addition of blinatumomab to consolidation chemotherapy represents a new standard of care for patients with newly diagnosed B lineage [acute lymphoblastic leukemia](#), who are in [remission](#) and have no measurable residual disease after induction chemotherapy," said Dr. Litzow, a Professor of Medicine at the Mayo Clinic in Rochester, Minnesota.

Current treatments for newly-diagnosed ALL frequently lead to remission. Still, unfortunately, [relapses](#) often occur in patients, leading to poor survival rates even in those with no measurable residual disease (MRD) after induction chemotherapy. An MRD test looks for any [cancer cells](#) that were not killed by cancer treatments.

The goal of the E1910 trial was to further improve overall survival in patients with a better prognosis, defined as in complete remission and MRD negative (

Citation: Trial demonstrates acute lymphoblastic leukemia treatment advance (2022, December 13) retrieved 13 May 2024 from

<https://medicalxpress.com/news/2022-12-trial-acute-lymphoblastic-leukemia-treatment.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.